Saturday 17 October 2026
Export ALLR’s income statement to Excel — free account
Allarity Therapeutics, Inc.
ALLR Healthcare Biotechnology
Allarity Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $320,000.00. In the quarter to June 2026, EPS fell 40.0%, free cash flow grew 53.2% and total debt rose 3.56%, each against the same quarter a year earlier.
0.90
0.07
+8.43%
Follow ALLR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (157.09%) | (87.92%) | (103.80%) | (122.61%) |
+8 more TTM periods Free account |
|
| (46.26%) | (34.80%) | (54.91%) | (74.37%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(348.81%) | (162.56%) | (114.28%) | (127.47%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.88) | (1.07) | (1.05) | (1.00) | |
Free Cash Flow |
(14.08) | (17.01) | (15.15) | (14.78) | |
Capital Expenditures |
(0.37) | (0.39) | (0.33) | — | |
| Other line items | |||||
Cash ROIC |
(44.08%) | (44.60%) | (58.45%) | (48.80%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(10.15) | (34.33) | (68.14) | (84.60) | |
Operating CF/Net income |
1.11 | 1.48 | 1.32 | 0.97 | |
Depreciation/Fixed assets |
(0.07) | (0.12) | (0.04) | (0.06) | |
Capex/Depreciation |
13.21 | 7.76 | 25.15 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.86) | (1.04) | (1.03) | (1.00) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates